BiomEdit / Pipeline
Making biology programmable for animal health
We innovate. We target unmet needs in animal health and develop Programmable Veterinary Biologics™ to address them.
Featured Program — Infectious Disease
CPerf LLV* (BE-101) granted USDA Conditional Licensure.1
First Programmable Veterinary Biologic to reach commercial launch (Q4 2026)
First engineered probiotic bacterial biologic to achieve conditional licensure for poultry.
A new non-antibiotic approach for reducing the impact of necrotic enteritis.
Three focus areas. One BiomEdit platform.
Our Programmable Veterinary Biologics platform spans three focus areas: infectious disease, sustainability, and chronic disease. We engineer beneficial bacteria to perform specific biological functions, including producing nanobodies, peptides, or enzymes, or working together as microbial consortia. Our platform also incorporates technology acquired from Folium Science that selectively targets specific bacterial populations already present in the microbiome. These complementary approaches can be applied across livestock and companion animals, with in-house capabilities spanning discovery, development, regulatory, and commercialization.
Our pipeline3
Focus Area
Species
Stage 1
Discovery / Design
Stage 2
Candidate Optimization
Stage 3
In Vivo Proof of Concept
Stage 4
Pivotal Studies
Stage 5
Regulatory Approval / Launch Readiness
Stage 6
Commercial
BE-122 Dogs
Discovery / Design
Mechanism: Nanobody
Probiotic vectored antibodies designed to treat inflammatory bowel disease (IBD) in dogs, offering a potential alternative or complement to chronic corticosteroid therapy, with possible extension to cats.
BE-017 Cattle
Candidate Optimization
Mechanism: Microbial Consortia
A tailored microbial consortium that reshapes the rumen microbiome to lower methane emissions in dairy and beef cattle, improving productivity with potential for infrequent dosing in grazing herds.
BE-117 Cattle
Candidate Optimization
Mechanism: Nanobody & Peptide
A first-in-class engineered rumen strain that continuously delivers anti-methanogen peptide and nanobody biomolecules directly in the rumen of dairy and beef cattle, reducing enteric methane emissions while improving feed efficiency and productivity.
BE-105 Cats
Candidate Optimization / In Vivo Study
Mechanism: Peptide
A first-in-class engineered oral biologic that delivers a sustained GLP-1 receptor agonist directly in the gut, supporting chronic weight management in cats, with obesity as the initial target and diabetes and dog applications as future extensions.
BE-118 Poultry
Candidate Optimization / In Vivo Study
Mechanism: Nanobody
Probiotic vectored antibodies targeting HA antigens on the avian influenza (HPAI) virus, designed to reduce viral burden and shedding in poultry as a complement or alternative to conventional HPAI prevention.
BE-119 Swine
Candidate Optimization / In Vivo Study
Mechanism: Enzyme
A probiotic vectored enzyme therapeutic that aims to reduce E. coli-driven diarrhea in piglets and scours in calves, supporting gut health and growth without relying on antibiotics.
BEX1 (BiomElix® One) Poultry
Regulatory Approval / Launch Readiness. Approved by Brazil's MAPA.
Mechanism: CRISPR-based editing (Guided Biotic)
Built on CRISPR-based technology that selectively targets harmful bacteria, including Salmonella, while preserving beneficial microbes in the poultry gut microbiome. The BiomElix® One feed ingredient was approved by Brazil's Ministry of Agriculture and Livestock (MAPA) and determined as non-GMO by the Brazil Biotech authority (CTNBio). This product is part of BiomEdit's acquisition of the technology of Folium Science.
CPerf LLV*/(BE-101) Poultry
Regulatory / Launch Readiness. Conditional USDA licensure. Commercial launch Q4 2026.
Mechanism: Nanobody
A first-in-class engineered probiotic that secretes nanobodies against Clostridium perfringens toxins in the broiler gut, helping reduce the impact of necrotic enteritis (NE) on broilers without antibiotics. Has been shown to reduce NE-associated mortality and other NE effects.
Read more →Species Coverage
Our programs target challenges in poultry, swine, cattle, dogs, and cats.
1 USDA has issued a conditional license for the product CPerf LLV* in accordance with regulation 9 CFR 102.6.
3 Pipeline candidates in Stages 1-3 are investigational products. These products have not been approved by the FDA or USDA and are not available for commercial sale. Research and development timelines, regulatory pathways, and other pipeline information are subject to change as technical, clinical, and regulatory evaluations evolve.
Interested in what’s next for BiomEdit?
*Clostridium Perfringens Alpha Toxin and NetB Antibody Fragment, Live Limosilactobacillus Vector